Source: Channel News Asia.

Law & Home Affairs Minister K Shanmugam says that pharmaceutical companies are hiding their intentions behind a smokescreen when it comes to cannabis. He describes the trend of accepting cannabis medical use is driven by the “power of money and propoganda”.

Mr Shanmugam said this just before a joint statement by the Home Affairs and Health ministries which set out the government’s position the use of pharmaceutical products containing cannabinoids.

The ministries clearly differentiated between pharmaceutical products with potential therapeutic uses, and products containing unprocessed or raw cannabis which they affirm have addictive and harmful properties.

They said, “To date, there are no studies which have validated the claims of unprocessed or raw cannabis being able to treat medical conditions,”

In December, Thailand became the first country in Southeast Asia to legalise the use of cannabis for medical purposes. Malaysia and the Philippines have considered following suit.

Mr Shanmugam voiced his thoughts that pharmaceutical companies are pushing a different line for financial gain, Mr Shanmugam told the programme Insight, in an episode on the implications of Thailand’s legalisation of what some term medical cannabis.

He said, “The research, in our view, is quite clear. The Institute of Mental Health (IMH) did a review of 500 articles between 1964 and 2015 on the effects of cannabis. It causes serious brain damage. One in two get addicted.”

“The companies, which are interested in making money out of this – really dealing in destruction and death – have found a new way of arguing it.”

The studies reviewed by IMH were published in medical journals and other literature by international medical bodies. The IMH concluded that “cannabis consumption is associated with irreversible brain damage, brain shrinkage and serious mental/psychiatric illnesses.

On the other hand, they found that are some medicine with cannabinoid products that are scientifically researched and medically approved. These can be administered through pharmaceutical products such as oral solutions and sprays.

There is even published research, derived from clinical trials, on the potential uses of cannabinoids to manage seizures and epilepsy, cited the ministries.

However, they iterated that such cannabinoid pharmaceuticals will have to be reviewed by the Health Sciences Authority (HSA) before they can be registered for supply in Singapore.

“Manufacturers are required to substantiate the safety, quality and efficacy of the cannabinoid pharmaceuticals based on scientific evidence from clinical studies and data on the manufacturing process,” read the joint statement.

Mr Shanmugam continued by saying that company have taken that concept – the potential medical use of cannabinoids – and labelled it as ‘cannabis is good for you for medicinal purposes’, while spending a lot of money advertising it.

“Some governments, quite frankly, then also look at the potential tax revenues. Though that’s a bum game, because I think in the states that have legalised, they find that the cost associated with increased health-related problems far outstrip any tax revenues,” he added.

The minister dismissed the case for legalising it as “full of holes” and illogical. He also described the term “medical cannabis” as a way to “whitewash the whole subject”.

“If you want medical cannabis, what you’re really saying is certain cannabinoid compounds, which are already included in some medicines, which can be prescribed… So why do you need to go from there to consuming raw, unprocessed cannabis?” he questioned.

“For a medicinal purpose, if a doctor certifies the need for a certain type of medicine that has a cannabinoid compound, there’s no problem.”

Currently, there are strict frameworks in place for the supply, prescription, and dispensing of controlled drugs for medical purposes. These drugs can have to be prescribed by a Singapore doctor for the medical condition registered with the HSA.

The ministries asserted that the policies are underpinned by research. As such, the lack of scientific evidence of the safety and efficacy of raw cannabis use supports their position that cannabis should remain an illicit drug.

Asked if a clearer distinction between support for medical and illegal drug use is needed, he replied that people would understand if it were explained, instead of being perverted to serve propaganda.

“The pharmaceutical companies can’t go out there and say: We want you to buy more drugs, and we want to make more money out of you,” he added.

“So they try and persuade you that they’re doing this to your benefit because it’s ‘medicinal’, you see. It‘s bunkum.”

The public have called out Mr Shanmugam on his comments that pharmaceutical companies are pushing a different line for financial gain when it comes to cannabis, asking why tobacco and alcohol are still widely available in Singapore when both are highly addictive and harmful substances as well:

Some even pointed out that cannabis has been proven to be effective, especially for people suffering from chronic or terminal illnesses:

While one netizen asked why there’s such a fuss over cannabis for medical purposes when other stronger drugs are already being used in the hospital setting:

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments
You May Also Like

Anti-PAP sentiments take a new turn

Anti-People’s Action Party (PAP) sentiments seem to have taken a new turn.…

仅上半年就超越前两年记录 骨痛热症病例破5000宗

今年骨痛热症病例似乎有所增加,目前已有四宗骨痛热症死亡病例,每个月有数百宗新病例。 据报导,今年2月份,两名分别居住在勿洛的74岁年长者,和居住在后港的77岁年长者被骨痛热症夺命。而在3月份宏茂桥一名71岁的男子也因此病逝。 另有一名住在后港的63岁年长者也于本月逝世。国家环境局(NEA)指出,所有的死亡病例都发生在病例集中区。 据环境局2019年骨痛热症检测数据显示,今年首季度(1月至3月)的病例共有2223宗,其中有25宗为骨痛溢血热症。这比上个季度,即去年的10月至12月增加了87.9巴仙的病例,上个季度共记录了1183宗病例。 更令人不安的是,今年截至6月17日,我国骨痛热症比例已经达到了5184宗,远远超过了2018年的病例总数,2018年共记录了3285宗病例,而在2017年共有2771宗。 单单只是今年的一周内,即6月9日至15日,环境局就接获467宗骨痛热症病例的报告,比上一周多出了67宗。事实上,环境局的报告显示,在过去三个月,每周记录的骨痛热症病例都增加了四倍。 病例集中区增加一倍 截止本月17日,环境局也检测到本月的骨痛热症病例集中区,共多达112个集中区,比上个月增加了一个倍。这显示了环境局在首个季度确定的214个病例集中区,已经在过去的三个月中增加了很多。情况似乎在第二季度会变得更糟糕。 截止今天(19日),根据环境局的数据显示,一共确定了119个活跃的病例集中区,其中有33个被列为“已爆发10宗病例的高风险区”。首五个区域为: 1.兀兰6道、兀兰环、Cres、兀兰 70和70通道 2.兀兰…

K Shanmugam says politicians should focus on key issues like jobs and COVID-19 pandemic at hustings

Politicians should focus on addressing issues like jobs and the COVID-19 pandemic…